On Monday, October 20, the next meeting of the Transparency Council.
AOTMiT: The Transparency Council will look into Mounjaro and alcohol prevention, among other things
Published Oct. 17, 2025 07:10
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Mounjaro KwikPen (tirzepatidum)
for the indication: type 2 diabetes in patients treated with at least two hypoglycemic drugs, with HbA1c ≥ 7.5%, obesity (BMI ≥ 30 kg/m²) and very high cardiovascular risk, defined as:
(a) confirmed cardiovascular disease, or
(b) damage to other organs manifested by: proteinuria, left ventricular hypertrophy or retinopathy, or
(c) the presence of two or more major risk factors among the following:
- Age ≥ 55 years (men) or ≥ 60 years (women),
- dyslipidemia,
- hypertension,
- smoking.
2 Prepare a position paper on the evaluation of the drug Padcev (enfortumabum vedotini)
under the drug program B.141.FM "Treatment of patients with urothelial carcinoma (ICD-10: C61, C65, C66, C67, C68)".
3 Prepare a position paper on the evaluation of the drug Adcetris (brentuximabum vedotinum)
within the framework of the drug program B.77 "Treatment of patients with classical Hodgkin's lymphoma (ICD-10: C81)".
4 Prepare an opinion on the prevention of addiction to alcohol and other psychoactive substances
in adolescents and young adults
5. Preparation of a position on the medicinal product Ethide (ethionamide)
for the indication: multidrug-resistant pulmonary tuberculosis.
6. Preparation of a position paper on the medicinal product Aquipta (atogepantum)
for the indication: treatment of adult patients with drug-resistant chronic migraine.
7 Prepare an opinion on the use of combination therapy trastuzumab I.V. with pertuzumab
for the off-label indication: treatment of adult patients with locally advanced or metastatic adenocarcinoma of the biliary tract, with overexpression of the HER2 receptor or amplification of the HER2 gene, after documented failure of chemotherapy with cisplatin and gemcitabine or cisplatin and gemcitabine in combination with durvalumab (second or subsequent lines of treatment).
8. Prepare an opinion on the use of combination therapy dabrafenib with trametinib
in the off-label indication: treatment of adult patients with locally advanced or metastatic adenocarcinoma of the biliary tract with V600E mutation in the BRAF gene, after documented failure of chemotherapy with cisplatin and gemcitabine or cisplatin and gemcitabine in combination with durvalumab (second line of treatment).
9. Prepare an opinion on the draft health policy program of the local government unit
"Health policy program on prevention of infectious diseases in the Municipality of Nowiny for 2026-2030".
10. Prepare an opinion on the draft health policy program of the local self-government unit
"Health Policy Program on medical rehabilitation of residents of the Municipality of Malczyce for 2026-2029".
11. Prepare an opinion on the draft health policy program of the local government unit
"Prevention of diseases of the musculoskeletal system through rehabilitation for children and adolescents, economically active people and seniors" (city of Sulejów).
